MATTHEW DECLOUET: Open Payments
NPI 1518342310 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,052 in 130 payments from 19 companies in 2025. Trend: 2023 $1,027 · 2024 $1,896 · 2025 $2,052
Food & beverage: $2,052
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 25 | $329 |
| Otsuka America Pharmaceutical, Inc. | 18 | $278 |
| ABBVIE INC. | 24 | $238 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $220 |
| E.R. Squibb & Sons, L.L.C. | 4 | $168 |
| Vanda Pharmaceuticals Inc. | 10 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $141 |
| Bausch Health US, LLC | 4 | $80 |
| Janssen Pharmaceuticals, Inc | 3 | $77 |
| Corium, LLC | 2 | $54 |
Products named: ARISTADA, VRAYLAR, CAPLYTA, REXULTI, COBENFY, FANAPT, TRINTELLIX, SPRAVATO.
Industry payments across LA — which companies pay providers there.
